請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47705
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲,王榮德,林淑文 | |
dc.contributor.author | Ru-Fen Chen | en |
dc.contributor.author | 陳汝芬 | zh_TW |
dc.date.accessioned | 2021-06-15T06:13:44Z | - |
dc.date.available | 2016-01-01 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-12 | |
dc.identifier.citation | 1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S-98S.
2. AHFS Drug Information. In. USA: American Society of Health System Pharmacists; 2009. 3. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994;10:381-94. 4. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-33S. 5. Micromedex® Healthcare Series, (electronic version). In. Greenwood Village, Colorado, USA: Thomson Micromedex; 2010. 6. Chenhsu RY, Chiang SC, Chou MH, Lin MF. Long-term treatment with warfarin in Chinese population. Ann Pharmacother 2000;34:1395-401. 7. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30:416-44. 8. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414-9. 9. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med 2005;45:197-206. 10. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66. 11. Da Silva MS, Sobel M. Anticoagulants: to bleed or not to bleed, that is the question. Semin Vasc Surg 2002;15:256-67. 12. 陳雅婷. 使用全民健康保險研究資料庫研究warfarin處方形態及一級交互作用之風險分析. 台北: 國立台灣大學; 2010. 13. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:257S-98S. 14. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med 1992;117:878-9. 15. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-78. 16. Demirkan K, Stephens MA, Newman KP, Self TH. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000;93:448-54; quiz 55. 17. Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm 2006;12:640-8. 18. Ariesen MJ, Tangelder MJ, Lawson JA, Eikelboom BC, Grobbee DE, Algra A. Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study. Eur J Vasc Endovasc Surg 2005;30:154-9. 19. Johnsen SP, Sorensen HT, Mellemkjoer L, et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 2001;86:563-8. 20. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94:537-43. 21. Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005;61:439-44. 22. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008;25:151-9. 23. 段曉涵. 運用健保資料庫分析腦中風病人併用Warfarin與阿斯匹靈之分佈及相關因素. 桃園: 長庚大學; 2008. 24. 賴榮年. 台灣抗凝血西藥及非類固醇止痛藥與科學中藥併用及交互作用之藥物流行病學研究. In. 臺北: 行政院衛生署中醫藥委員會; 2009. 25. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995;90:206-10. 26. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1997;92:419-24. 27. Yamada T, Alpers DH. Principles of clinical gastroenterology. Hoboken, NJ: Wiley-Blackwell; 2008. 28. Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J. The national ASGE survey on upper gastrointestinal bleeding. I. Study design and baseline data. Gastrointest Endosc 1981;27:73-9. 29. Zuckerman GR, Prakash C. Acute lower intestinal bleeding. Part II: etiology, therapy, and outcomes. Gastrointest Endosc 1999;49:228-38. 30. Yamada T, Alpers DH. Textbook of gastroenterology. Hoboken, NJ: Blackwell Pub.; 2009. 31. Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985;142:439-44. 32. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109:681-91. 33. Konturek PC, Ernst H, Konturek SJ, et al. Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori. Gut 1997;40:463-9. 34. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008;66:76-81. 35. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-84. 36. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31. 37. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72. 38. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40. 39. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007;177:347-51. 40. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999;319:1106-9. 41. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163:59-64. 42. Mackay A, Stevenson RD. Gastric ulceration induced by spironolactone. Lancet 1977;1:481. 43. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006;333:330. 44. Gulmez SE, Lassen AT, Aalykke C, et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008;66:294-9. 45. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28. 46. National Health Insurance Research Database, Taiwan. (Accessed at http://www.nhri.org.tw/nhird/en/index.htm.) 47. Tatro DS. Drug Intercation Facts. St. Louis, MO.: Walters Kluwer Health; 2010. 48. Micromedex® Healthcare Series, (electronic version). In. Greenwood Village, Colorado, USA: Thomson Micromedex; 2009. 49. 黃淑萍. 某醫學中心心房顫動病患特性與抗血栓劑處方形態之研究. 臺北: 國立台灣大學; 2004. 50. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9. 51. Al-Mondhiry H, Galanakis D. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis. J Lab Clin Med 1987;110:726-33. 52. Hsiao FY, Tsai YW, Huang WF, et al. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther 2009;31:2038-47. 53. 王榮德. 流行病學方法論 猜測與否證的研究. 臺北市: 健康文化; 2000. 54. 彭昭英. SAS 1-2-3. 臺北市: 格致總經銷; 2008. 55. Hu F-C. Introduction to modeling and analysis methods of survival data, lecture notes Taipei, Taiwan, R.O.C.; 2000. 56. http://www.whocc.no/ddd/definition_and_general_considera/. 57. DiPiro JT. Pharmacotherapy : a pathophysiologic approach. New York: McGraw-Hill Medical; 2008. 58. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167:117-24. 59. Fuster V, Ryden LE, Cannom DS, et al. [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. Rev Port Cardiol 2007;26:383-446. 60. Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. Am J Med 1988;84:683-90. 61. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994;35:464-6. 62. Scordo MG, Melhus H, Stjernberg E, Edvardsson AM, Wadelius M. Warfarin-noscapine interaction: a series of four case reports. Ann Pharmacother 2008;42:448-50. 63. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010;123:151-7. 64. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005;165:189-92. 65. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008;168:180-5. 66. Cheetham TC, Levy G, Niu F, Bixler F. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 2009;43:1765-73. 67. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997;31:1006-8. 68. Mercadal Orfila G, Gracia Garcia B, Leiva Badosa E, Perayre Badia M, Reynaldo Martinez C, Jodar Masanes R. Retrospective assessment of potential interaction between levofloxacin and warfarin. Pharm World Sci 2009;31:224-9. 69. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106. 70. Hochman R, Clark J, Rolla A, Thomas S, Kaldany A, D'Elia JA. Bleeding in patients with infections. Are antibiotics helping or hurting? Arch Intern Med 1982;142:1440-2. 71. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 2008;84:581-8. 72. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52. 73. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8. 74. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002;121:19-23. 75. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988;148:1779-81. 76. Martinowitz U, Rabinovich J, Goldfarb D, Many A, Bank H. Interaction between warfarin sodium and amiodarone. N Engl J Med 1981;304:671-2. 77. Lu Y, Won KA, Nelson BJ, Qi D, Rausch DJ, Asinger RW. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm 2008;65:947-52. 78. Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. Ann Pharmacother 1998;32:765-8. 79. Bjornsson TD, Meffin PJ, Swezey SE, Blaschke TF. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. J Pharmacol Exp Ther 1979;210:322-6. 80. Aldridge MA, Ito MK. Fenofibrate and warfarin interaction. Pharmacotherapy 2001;21:886-9. 81. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Ann Pharmacother 2000;34:666-7. 82. Linder JD, Monkemuller KE, Davis JV, Wilcox CM. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000;93:930-2. 83. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27. 84. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-32. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47705 | - |
dc.description.abstract | 研究背景
消化道出血是warfarin最常見的嚴重副作用,交互作用亦提高出血的風險。目前國內並沒有完整針對warfarin併用交互作用藥品與消化道出血間關聯的研究,因此希望透過本研究提供醫療人員藥品流行病學資料,以保障用藥安全。 研究目的 利用具有全國代表性之健保資料庫,分析warfarin使用者的消化道出血發生率、併用一級交互作用藥品是否增加消化道出血風險,以及併用交互作用藥品之出血病人群基本特性。 研究方法 以1997年至2007年臺灣全民健保資料庫100萬人抽樣歸人檔為材料,進行回溯性世代研究;研究族群為1998年1月1日至2007年12月31日新使用warfarin病人,從初次warfarin開方日追蹤至研究終點(第一次消化道出血急診或住院事件)或2007年12月31日前最後一筆申報資料,收集warfarin、56種一級交互作用藥品、潛在增加消化道出血用藥紀錄(包含天數及劑量)及共病症。 計算完全未使用一級交互作用藥品(warfarin alone)及併用個別一級交互作用藥品病人群之消化道出血粗發生率,並分析併用交互作用藥品病人中出血族群特性。 利用time dependent Cox proportional hazard model進行研究終點事件分析,並納入年齡、性別、消化道出血相關用藥及共病症等變項校正。 研究結果 10年研究期間共有5251位warfarin新使用者,平均年齡為63.3歲,男性佔多數(53.8%),warfarin使用期間或處方結束日之14天內第一次消化道出血住院事件共有189人,粗發生率為每100人年2.9人年,出血部位以消化道潰瘍相關出血佔大多數共60人(31.7%),warfarin alone病人群出血發生率每100人年4.6人。在本研究定義之56種一級交互作用藥品中,共有43種(76.8%)一級交互作用藥品於研究期間與warfarin併用,其中19種在併用期間發生消化道出血事件,出血個案數大於3人之個別藥品出血發生率分為ketoprofen每100人年51.5人、naproxen 23.6.人、fenofibrate 12.6人、cilostazol 5.5人、aspirin 4.7人、celecoxib 4.1人、ginkgo biloba 3.6人、amiodarone 2.1人及clopidogrel 2.4人,而併用交互作用藥品病人群中,出血族群最常見的特性為年齡大於70歲,warfarin劑量並未依年齡調降,消化道出血相關病史較多,同時使用增加消化道出血風險的藥品。 Cox model分析結果顯示, warfarin使用者在出血前14天,若併用heparin,每增加一個DDD (defined daily dose)的heparin (10000U),消化道出血風險(hazard ratio, HR)增為2.614倍(1.779-3.842);併用levofloxacin,每增加一個DDD (500 mg)的levofloxacin,HR=1.232 (1.017-1.494);併用aspirin每增加一個DDD (100 mg)的aspirin,HR=1.027 (1.010-1.044);併用carboplatin,每增加一毫克的carboplatin,HR=1.025 (1.016-1.033);併用ketoprofen,每增加一天併用ketoprofen,HR=1.187 (1.035-1.362)。此外,病人本身具有共病症(如鬱血性心衰竭、凝血病變、消化道潰瘍或出血、消化道發炎、食道靜脈曲張、馬魏氏症候群及洗腎)、使用非類固醇抗發炎藥、皮質固醇及利尿劑(spironolactone)皆會增加出血風險。 結論 Warfarin使用者併用43種一級交互作用藥品中,只有其中5種(11.6%)與消化道出血住院事件有顯著相關性。部分風險藥品或共病症造成消化道出血風險反而比warfarin及一級交互作用藥品高,但本研究受限於健保資料庫,無法將病人服藥順從性、warfarin與食物、中草藥之交互作用一併分析。雖然研究結果顯示併用一級交互作用藥品與消化道出血風險不如預期的高,但如果病人年紀大於70歲,使用多種增加消化道出血風險之藥品及有消化道潰瘍出血病史時,必須更積極監測及調整warfarin使用劑量,保障用藥安全。 | zh_TW |
dc.description.abstract | Background
Gastrointestinal (GI) bleeding was the most frequent complication of warfarin. Drug-drug interactions may increase this risk. In Taiwan, there is no comprehensive study to investigate the risk of GI bleeding associated with potentially significant warfarin drug interactions. Objective Using National Health Insurance Database of Taiwan to evaluate the incidence rate of GI bleeding in warfarin users, risk of GI bleeding associated with potentially significant warfarin drug interactions, and characteristics of warfarin users who were hospitalized due to bleeding. Methods This retrospective cohort study analyzed National Health Insurance Database with one million randomly selected individuals from January, 1997 until December, 2007. The study population (warfarin new users) started warfarin after January, 1998. They were followed from the first day of warfarin prescribing until the firtst GI bleeding complication requiring hospitalization or the last claim data befor December 2007. We collected all claim data of warfarin, 56 potentially significant interacting drugs (PIDs), risk medication and comorbidity. We calculated the crude incidence of GI bleeding events during warfarin exposure alone period (without PIDs) and periods of concomitant exposure (with PIDs), and also analyzed characteristics of patients with bleeding events. The time dependent Cox proportional hazard model was performed to determine the hazard ratio (HR) of risk factors associated with GI bleeding, adjusted with age, sex, risk medication and comorbidity. Results There were 5251 warfarin new users in the 10 year study period. Their mean age was 63.3 years old. More than half (53.8%) were male. A total of 189 patients were hospitalized for GI bleeding. The major etiology, peptic ulcer bleeding, was found in 60 patients (31.7%). The crude incidence rate of total warfarin users was 2.9 per 100 person-year (per 100 PY). During warfarin exposure alone, the incidence rate was 4.6 per 100 PY. Forty-three (76.8%) out of 56 PIDs were taken concomitantly by warfarin users. Among 43 PIDs, GI bleeding events occurred during combinationof 19 PIDs and warfarin. The incidence rate of the PIDs with more than 3 bleeding events were ketoprofen (51.5 per 100 PY), naproxen (23.6 per 100 PY), fenofibrate (12.6 per 100 PY) , cilostazol (5.5 per 100 PY), aspirin (4.7 per 100 PY) , celecoxib (4.1 per 100 PY), ginkgo biloba (3.6 per 100 PY), clopidogrel (2.4 per 100 PY) and amiodarone (2.1 per 100 PY). Patients who suffered from bleeding were usually older than 70 years old without dosing adjustment (reduction), more comorbidities prone to GI bleeding and taking risk medication. The Cox model analysis revealed that adjusted HRs of warfarin-PID for GI bleeding were 2.614 (1.779-3.842), 1.232(1.017-1.494), 1.027(1.010-1.044), 1.025 (1.016-1.033), 1.187 (1.035-1.362), for increasing 1 defined daily dose (DDD, 10000U) of heparin, increasing one DDD (500 mg) of levofloxacin, increasing one DDD (100 mg) of aspirin, increasing 1 mg of carboplatin, increasing one day of ketoprofen, respectively. In addition, patients with comorbidity (congestive heart failure, coagulopathy, peptic ulcer or bleeding, esophagitis, gastritis, duodenitis, esophageal varices, Mallory-weiss tear, renal dialysis), or using risk medication (NSAIDs, corticosteroid, spironolactone) had a higher risk of bleeding. Conclusions Warfarin users in this study used 43 PIDs and only 5 PIDs (11.6%) significantly increased the risk of GI bleeding. On the other hand, some risk medication or comorbidities caused higher risk than warfarin and PIDs. This study, however, was limited by not able to access data regarding patient adherence, drug-food or herb interactions. Although the risk of PIDs was not as high as we expected, physicians or pharmacists should pay attention to elderly (age>70 years old), patients taking risk medications or with history of peptic ulcer or bleeding. It may ensure medication safety in these patient populations by close monitoring and adjusting warfarin dosing. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T06:13:44Z (GMT). No. of bitstreams: 1 ntu-99-R97451009-1.pdf: 699821 bytes, checksum: 5e2efa1d9de0aae749934d8979e47de4 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract v 圖目錄 x 表目錄 xi 第1章 文獻探討 1 1.1 warfarin簡介 1 1.1.1. 藥理學 1 1.1.2. 藥品動態學 2 1.1.3. 臨床上使用適應症、劑量及監測方式 2 1.2 warfarin之藥品交互作用機轉 3 1.3 使用warfarin之出血併發症及相關危險因子 4 1.4 warfarin併用交互作用藥品增加出血風險之相關研究 6 1.5 消化道出血 10 第2章 研究目的 12 第3章 研究方法 13 3.1 研究材料 13 3.2 研究設計、研究族群建立 14 3.2.1 研究設計 14 3.2.2 研究族群納入與排除條件 14 3.2.3 研究期間定義 15 3.2.4 一級交互作用藥品及藥品交互作用(Drug–Drug Interaction, DDI)定義 15 3.2.5 研究資料收集 17 3.2.6 消化道出血粗發生率(crude incidence rate) 22 3.2.7 併用一級交互作用藥品族群之基本特性分析 23 3.2.8 統計分析 25 第4章 研究結果 28 4.1 研究族群建立過程及特性分析 28 4.2 研究族群分組結果及特性分析 32 4.3 warfarin處方型態 35 4.4 併用一級交互作用藥品之盛行率分析 37 4.5 研究終點-消化道出血急診或住院事件 41 4.5.1. 粗發生率 42 4.5.2. 消化道出血事件存活分析 44 4.5.3. Warfarin alone病人群基本特性分析 60 4.5.4. warfarin併用一級交互作用藥品族群,出血與未出血族群基本特性分析 63 第5章 討論 99 5.1 併用一級交互作用藥品之盛行率分析 99 5.2 研究事件終點 100 5.2.1 消化道出血診斷 100 5.2.2 消化道出血事件存活分析 101 5.2.3 warfarin alone消化道出血粗發生率及病人群基本特性分析 104 5.2.4 併用一級交互作用藥品族群之基本特性分析 105 5.3. 研究限制 109 第6章 結論 110 參考文獻 111 附錄1、ICD-9-CM codes, A-codes for indication 117 附錄2、ICD-9-CM codes, A-codes for comorbidity 118 | |
dc.language.iso | zh-TW | |
dc.title | Warfarin併用一級交互作用藥品與消化道出血之風險分析 | zh_TW |
dc.title | Risk of Gastrointestinal Bleeding Associated with Potentially Significant Warfarin Drug Interactions | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李啟明,翁昭旼,賴榮年 | |
dc.subject.keyword | Warfarin,交互作用消化道出血,發生率,全民健康保險研究資料庫, | zh_TW |
dc.subject.keyword | Warfarin,drug drug interaction,gastrointestinal bleeding,incidence rate,National Health Insurance Research Database, | en |
dc.relation.page | 119 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 683.42 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。